China’s AIM Vaccine Launches Clinical Trials for mRNA Shingles Vaccine in China and US
China-based AIM Vaccine Co., Ltd (HKG: 6660) announced the initiation of clinical trials for its...
HKG: 6660
AIM Vaccine’s Serum-Free Rabies Vaccine Accepted for Review by NMPA
China-based AIM Vaccine Co., Ltd (HKG: 6660) announced that its market filing for a serum-free...
AIM Vaccine’s mRNA-based Shingles Vaccine Receives FDA Approval for Clinical Study
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving approval from the US Food...
AIM Vaccine Co. Ltd Announces Market Filing for Innovative Serum-Free Rabies Vaccine
China-based AIM Vaccine Co., Ltd (HKG: 6660) announced plans to file for market approval for...
AIM Vaccine Co. Ltd Receives NMPA Approval for Human Diploid Rabies Vaccine Trial
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving approval from the National Medical...
AIM Vaccine Leverages DeepSeek AI to Optimize mRNA Shingles Vaccine Design
China-based AIM Vaccine Co., Ltd (HKG: 6660) has filed its mRNA-based shingles vaccine with the...
AIM Vaccine Co., Ltd Receives NMPA Clearance for Innovative Cell-Based Influenza Vaccine
AIM Vaccine Co., Ltd (HKG: 6660), a China-based biopharmaceutical company, has announced that it has...
AIM Vaccine Co., Ltd Receives NMPA Approval for Second-Gen Tetanus Vaccine Clinical Trial
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced that it has received clinical trial...
AIM Vaccine Submits Market Filing for 13-Valent Pneumococcal Conjugate Vaccine in China
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the submission of a market filing...
AIM Vaccine Secures NMPA Approval for mRNA Vaccine Targeting RSV
AIM Vaccine Co., Ltd (HKG: 6660), based in China, has received clinical trial approval from...
AIM Vaccine Submits Pre-IND Applications for mRNA Vaccines Targeting RSV and Herpes Zoster to NMPA
AIM Vaccine Co., Ltd (HKG: 6660), a biopharmaceutical company based in China, has announced the...
AIM Vaccine Advances Pneumococcal Vaccine and Initiates Phase II Meningococcal Study
AIM Vaccine Co., Ltd (HKG: 6660) has delivered a series of updates on the development...
Quinovare Partners with AIM Vaccine to Enhance Vaccine Accessibility in China
Quinovare Medical Technology Co., Ltd., a China-based specialist in needle-free injectors, has announced a strategic...
AIM Vaccine’s Serum-Free Rabies Vaccine Completes Phase III Safety Observation
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the successful completion of the 7-day...
AIM Vaccine Co., Ltd Launches Phase III Trial for 23-Valent Pneumococcal Vaccine
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the commencement of a Phase III...
AIM Vaccine Receives NMPA Approval for mRNA Vaccine Clinical Study Targeting COVID-19 Variants
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving approval from the National Medical...
AIM Vaccine’s Omicron BA.5 mRNA Vaccine Shows 73.16% Efficacy in China Trial
China-based AIM Vaccine Co., Ltd (HKG: 6660) has revealed the protective efficacy of its Omicron...
AIM Vaccine Initiates Phase I Clinical Study for MCV4 Meningococcal Vaccine in China
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the initiation of a single-center, open...
AIM Vaccine Gains Approvals for COVID-19 mRNA Vaccine Trials in Pakistan
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving separate approvals in Pakistan to...
AIM Vaccine Receives CDE Approval for Serum-Free Rabies Vaccine Trial
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving clinical trial approval from the...